RAC

1.11%

$1.83 race oncology ltd

Ann: Chief Medical Officer Appointment, page-83

First 83 Last

Share
Profile

Follow
IndexInvestor

8,371 Posts.

1379

12/11/22

21:49

Post #: 64738444
Share

Originally posted by KingBuzzo: ↑

Edit - replying to @IndexInvestor above, the reply seems broken for me at the moment.

From the at Advonate web site:The EMD AML trial expansion into Europe was announced on 8 June 2022 (5 months ago). Race don't have a European team, so I'm speculating, but looking at what their expertise is, it would make sense that Advonate Clinical was engaged by Race around this time. Actually, I'd say likely they were engaged even earlier as Race would probably have started work on this expansion prior to the announcement. There's no doubt a huge amount of work to navigate through the European regulatory structure and no way David could do all of this himself as well as concurrently working on the Australian EMD and other upcoming trials. Advonate (on paper) look to be the ideal outfit Race would engage to help the clinical team get the European trial expansion up and running. If that's the case, Ajay may have been getting up to speed on the topics you mention, as well as possibly being in the drivers seat for the European trial expansion, for the last 6 months or more.

In regards to recruiting a new CMO, by the time you advertise, wait for applicants, conduct interviews, discuss and rank front-runners, negotiate offers, etc., three months (assuming David gave 3 months notice as per his contract and not more) is barely enough time to complete recruitment unless the ideal candidate drops right into your lap. Once they do find someone, yes, they'll no doubt have a ramp-up period, but Ajay and Advonate would likely still be around during (and probably well after) this transition. That's one of the advantages of using a consultancy.

Also from the Advonate web site:

So it looks like it's not necessarily an unusual thing that some of these high level roles can be filled by consultants, especially in smaller companies.

Conclusion: This change may not be ideal, but may not be as disruptive as it seems on first glance.

Expand

If Advonate were engaged some time ago, then I agree that the discontinuity is less than it appears.

But what evidence is there that they were engaged some time ago? Surely it would have been mentioned in this latest announcement if Advonate had already been working for RAC? Why keep that secret?

I agree that three months is short to recruit a CMO. Which raises the question of why have a notice period of only three months.

RAC Price at posting: $2.20 Sentiment: Hold Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

Microcap Wrap: 5 explorers with news out today

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

RCE

Recce's R327 found effective against E.coli during clinical trial

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

There are more pages in this discussion • 12 more messages in this thread...

First 83 Last

Add RAC (ASX) to my watchlist

(20min delay)
Last $1.83		Change 0.020(1.11%)		Mkt cap ! $310.7M

Open	High	Low	Value	Volume
$1.81	$1.83	$1.79	$142.0K	78.77K

Buyers (Bids)

No.	Vol.	Price($)
1	500	$1.81

Sellers (Offers)

Price($)	Vol.	No.
$1.83	641	1

View Market Depth

No.	Vol.	Price($)
1	500	1.810
3	7009	1.790
1	450	1.780
1	651	1.775
3	17043	1.770

Price($)	Vol.	No.
1.825	641	1
1.830	1209	2
1.835	651	1
1.840	4651	3
1.845	2746	1

Last trade - 16.10pm 28/06/2024 (20 minute delay)

RAC (ASX) Chart

Ann: Chief Medical Officer Appointment, page-83

Microcap Wrap: 5 explorers with news out today

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Recce's R327 found effective against E.coli during clinical trial

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Ava Risk Group expands US presence with A$0.7M Substation Deal

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Chief Medical Officer Appointment, page-83

Top Stories

Microcap Wrap: 5 explorers with news out today

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Recce's R327 found effective against E.coli during clinical trial

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Ava Risk Group expands US presence with A$0.7M Substation Deal

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News